Start here if you're new
what it is
LeonaBio develops drug candidates for metastatic breast cancer and other hard-to-treat diseases.
how it gets paid
Last year Leonabio made n/a in revenue. Lasofoxifene program was the main engine at $0M, or 25% of sales.
what just happened
Quarterly EPS came in at -$5.80, while revenue stayed at $0M.
At a glance
C+ balance sheet — struggling to keep the lights on
50/100 earnings predictability — expect surprises
-$25.20 fy2024 eps est
1.4 beta
~$72M market cap
xvary composite: 24/100 — weak
What they do
LeonaBio develops drug candidates for metastatic breast cancer and other hard-to-treat diseases.
You are paying for one late-stage shot and one early shot. The company says lasofoxifene is in Phase 3, which means late-stage trial, so one readout matters more than sales do. It also says the company has 26 employees and $90M upfront financing, with up to $146M more from warrants.
How they make money
n/a
annual revenue
Lasofoxifene program
$0M
ATH-1105 program
$0M
Pipeline rights and development
$0M
Corporate and other
$0M
The products that matter
lead oncology program
lasofoxifene
single lead asset
this is the equity story. with $0.00 in quarterly revenue, you are still underwriting trial outcomes more than commercial execution.
the bet
supporting clinical pipeline
pipeline optionality
thin on this page
the snapshot does not show a second validated business line. until more programs become concrete, the market is treating LONA like one main asset with some optionality attached.
not enough yet
capital base
cash runway
implied constraint
the page gives you a C+ balance sheet, $0M of long-term debt, and a -$37.72M trailing loss. no debt helps. the loss still tells you funding is the bottleneck.
time
Key numbers
$0M
revenue
No sales means the stock is priced on trial news and cash, not on a business that already works.
$72M
market cap
That is the whole equity story today. One clinical update can rewrite most of it.
$90M
upfront cash
That money buys time. It does not buy sales.
26
employees
A 26-person company cannot hide behind scale. It needs data.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $0M (1% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for LONA right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Quarterly EPS came in at -$5.80, while revenue stayed at $0M.
Value Line puts FY2024 EPS at -$25.20. Yahoo Finance shows trailing EPS at -$6.72. You are looking at a pre-revenue biotech with losses and no sales buffer.
$0M
revenue
$5.80
eps
n/a
n/a
quarterly loss
The -$5.80 EPS matters because there is no revenue to offset it.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is lasofoxifene failing to produce convincing clinical data. with $0.00 in quarterly revenue, this company does not have another engine to lean on.
med
lasofoxifene clinical disappointment
This is the whole stock story right now. If the key data fail to support the thesis, the market has few other reasons to assign much value to the equity.
with $0.00 in quarterly revenue and a $30.21M market cap, a weak readout would hit valuation and financing leverage at the same time.
med
cash burn forces dilution
A -$37.72M trailing net loss on a $30.21M market cap is the math problem. If timelines stretch, new capital usually arrives before new certainty does.
the company has no revenue base to self-fund development, so outside capital can turn from support into the story itself.
med
the pipeline is too narrow
This page is still dominated by one lead asset. That concentration makes every update more binary and gives investors fewer ways to stay patient.
if the market stops assigning value to anything beyond lasofoxifene, the stock trades like a single-program option with a short clock.
No sales, one Phase 3 asset, and financing dependence is a rough mix when your whole business is still a promise.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
the next clinical milestone
This stock gets repriced on catalysts, not on routine operating momentum. If management pushes timelines, your risk went up even if the science did not change.
metric
net loss versus market cap
Keep -$37.72M next to $30.21M. When annual loss exceeds equity value, financing terms matter almost as much as trial design.
risk
dilution probability
A pre-revenue biotech can survive bad optics. It cannot survive running out of money. Watch for any sign that cash needs arrive before data do.
trend
whether the rally keeps outrunning the business
A 146.87% one-year gain tells you traders noticed. It does not tell you the company de-risked. If price stays hot while the operating picture stays thin, volatility usually follows.
Analyst rankings
short-term outlook
mixed
coverage is thin here. in human-speak, there is no broad analyst crowd doing the work for you.
risk profile
volatile
beta: 1.4. this stock has moved more than the market, and clinical headlines can make that look conservative.
chart momentum
catalyst-led
this name trades on readouts, financing expectations, and sentiment bursts. the tape matters. the next piece of evidence matters more.
earnings predictability
50/100
that is a coin-flip score. in plain english: the financials are not stable enough to anchor the stock by themselves.
source: institutional data
Institutional activity
institutional ownership data for LONA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$6
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive